Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Tumor-specific inhibitory action of decorin on different hepatoma cell lines.

Horváth Z, Reszegi A, Szilák L, Dankó T, Kovalszky I, Baghy K.

Cell Signal. 2019 Oct;62:109354. doi: 10.1016/j.cellsig.2019.109354. Epub 2019 Jul 2.

PMID:
31271881
2.

Proteomic identification of membrane-associated placental protein 4 (MP4) as perlecan and characterization of its placental expression in normal and pathologic pregnancies.

Szenasi NL, Toth E, Balogh A, Juhasz K, Karaszi K, Ozohanics O, Gelencser Z, Kiraly P, Hargitai B, Drahos L, Hupuczi P, Kovalszky I, Papp Z, Than NG.

PeerJ. 2019 Jun 20;7:e6982. doi: 10.7717/peerj.6982. eCollection 2019.

3.

Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.

Reiniger L, Téglási V, Pipek O, Rojkó L, Glasz T, Vágvölgyi A, Kovalszky I, Gyulai M, Lohinai Z, Rásó E, Tímár J, Döme B, Szállási Z, Moldvay J.

Acta Oncol. 2019 Aug;58(8):1087-1094. doi: 10.1080/0284186X.2019.1598575. Epub 2019 Apr 19.

PMID:
31002007
4.

Syndecan-1 in Liver Diseases.

Regős E, Karászi K, Reszegi A, Kiss A, Schaff Z, Baghy K, Kovalszky I.

Pathol Oncol Res. 2019 Mar 2. doi: 10.1007/s12253-019-00617-0. [Epub ahead of print]

PMID:
30826971
5.

Increased placental expression of Placental Protein 5 (PP5) / Tissue Factor Pathway Inhibitor-2 (TFPI-2) in women with preeclampsia and HELLP syndrome: Relevance to impaired trophoblast invasion?

Karaszi K, Szabo S, Juhasz K, Kiraly P, Kocsis-Deak B, Hargitai B, Krenacs T, Hupuczi P, Erez O, Papp Z, Kovalszky I, Than NG.

Placenta. 2019 Jan 15;76:30-39. doi: 10.1016/j.placenta.2019.01.011. Epub 2019 Jan 19.

PMID:
30803712
6.

Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma.

Mervai Z, Reszegi A, Miklya I, Knoll J, Schaff Z, Kovalszky I, Baghy K.

Pathol Oncol Res. 2019 Feb 8. doi: 10.1007/s12253-019-00603-6. [Epub ahead of print]

PMID:
30734151
7.

Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.

Lendvai G, Szekerczés T, Illyés I, Dóra R, Kontsek E, Gógl A, Kiss A, Werling K, Kovalszky I, Schaff Z, Borka K.

Pathol Oncol Res. 2018 Nov 17. doi: 10.1007/s12253-018-0491-8. [Epub ahead of print] Review.

PMID:
30448973
8.

MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma.

Lendvai G, Szekerczés T, Gyöngyösi B, Schlachter K, Kontsek E, Pesti A, Patonai A, Werling K, Kovalszky I, Schaff Z, Kiss A.

Pathol Oncol Res. 2019 Jul;25(3):1103-1109. doi: 10.1007/s12253-018-0528-z. Epub 2018 Nov 9.

PMID:
30411298
9.

Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia.

Than NG, Romero R, Tarca AL, Kekesi KA, Xu Y, Xu Z, Juhasz K, Bhatti G, Leavitt RJ, Gelencser Z, Palhalmi J, Chung TH, Gyorffy BA, Orosz L, Demeter A, Szecsi A, Hunyadi-Gulyas E, Darula Z, Simor A, Eder K, Szabo S, Topping V, El-Azzamy H, LaJeunesse C, Balogh A, Szalai G, Land S, Torok O, Dong Z, Kovalszky I, Falus A, Meiri H, Draghici S, Hassan SS, Chaiworapongsa T, Krispin M, Knöfler M, Erez O, Burton GJ, Kim CJ, Juhasz G, Papp Z.

Front Immunol. 2018 Aug 8;9:1661. doi: 10.3389/fimmu.2018.01661. eCollection 2018.

10.

Chronic Hyperglycaemia Induced Alterations of Hepatic Stellate Cells Differ from the Effect of TGFB1, and Point toward Metabolic Stress.

Kiss K, Regős E, Rada K, Firneisz G, Baghy K, Kovalszky I.

Pathol Oncol Res. 2018 Aug 14. doi: 10.1007/s12253-018-0458-9. [Epub ahead of print]

PMID:
30109568
11.

Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer.

Krafft U, Reis H, Ingenwerth M, Kovalszky I, Becker M, Niedworok C, Darr C, Nyirády P, Hadaschik B, Szarvas T.

Pathol Oncol Res. 2018 Jul 17. doi: 10.1007/s12253-018-0447-z. [Epub ahead of print]

PMID:
30019121
12.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

13.

Chemodiversity of Cirsium fruits: Antiproliferative lignans, neolignans and sesquineolignans as chemotaxonomic markers.

Könye R, Tóth G, Sólyomváry A, Mervai Z, Zürn M, Baghy K, Kovalszky I, Horváth P, Molnár-Perl I, Noszál B, Béni S, Boldizsár I.

Fitoterapia. 2018 Jun;127:413-419. doi: 10.1016/j.fitote.2018.04.007. Epub 2018 Apr 11.

PMID:
29653155
14.

Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.

Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Kubik A, Romics M, Kovalszky I, Reis H, Hadaschik B, Shariat SF, Kramer G.

Urol Oncol. 2018 Jun;36(6):312.e9-312.e15. doi: 10.1016/j.urolonc.2018.03.010. Epub 2018 Apr 5.

PMID:
29628317
15.

NSCLC molecular testing in Central and Eastern European countries.

Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, Kovalszky I, Olszewski W, Oz B, Plank L, Timar J.

BMC Cancer. 2018 Mar 9;18(1):269. doi: 10.1186/s12885-018-4023-4.

16.

Extracellular matrix functions in lung cancer.

Götte M, Kovalszky I.

Matrix Biol. 2018 Nov;73:105-121. doi: 10.1016/j.matbio.2018.02.018. Epub 2018 Feb 27. Review. No abstract available.

PMID:
29499357
17.

Syndecan-1 inhibits early stages of liver fibrogenesis by interfering with TGFβ1 action and upregulating MMP14.

Regős E, Abdelfattah HH, Reszegi A, Szilák L, Werling K, Szabó G, Kiss A, Schaff Z, Kovalszky I, Baghy K.

Matrix Biol. 2018 Aug;68-69:474-489. doi: 10.1016/j.matbio.2018.02.008. Epub 2018 Feb 16.

PMID:
29454902
18.

Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse.

Mervai Z, Egedi K, Kovalszky I, Baghy K.

BMC Cancer. 2018 Feb 7;18(1):157. doi: 10.1186/s12885-018-4068-4.

19.

[Systemic mastocytosis with progressive disease course].

Várkonyi J, Szombath G, Vályi-Nagy A, Csomor J, Egedi K, Kovalszky I, Tölgyesi K, Szerafin L, Tóth L, Soós G, Masszi T.

Orv Hetil. 2018 Feb;159(5):192-196. doi: 10.1556/650.2018.30978. Hungarian.

PMID:
29376426
20.

The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.

Felkai L, Bánusz R, Kovalszky I, Sápi Z, Garami M, Papp G, Karászi K, Varga E, Csóka M.

Pathol Oncol Res. 2019 Jan;25(1):217-224. doi: 10.1007/s12253-017-0332-1. Epub 2017 Oct 28.

PMID:
29081033
21.

Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform.

Péterfia B, Kalmár A, Patai ÁV, Csabai I, Bodor A, Micsik T, Wichmann B, Egedi K, Hollósi P, Kovalszky I, Tulassay Z, Molnár B.

J Cancer. 2017 Jan 12;8(2):162-173. doi: 10.7150/jca.16037. eCollection 2017. Erratum in: J Cancer. 2018 Jul 1;9(15):2743.

22.

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis.

Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, Renyi-Vamos F, Klepetko W, Dome B, Hegedus B.

Sci Rep. 2017 Jan 4;7:39721. doi: 10.1038/srep39721.

23.

Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.

Butz H, Németh K, Czenke D, Likó I, Czirják S, Zivkovic V, Baghy K, Korbonits M, Kovalszky I, Igaz P, Rácz K, Patócs A.

Pathol Oncol Res. 2017 Jul;23(3):633-641. doi: 10.1007/s12253-016-0163-5. Epub 2016 Dec 21.

PMID:
28004354
24.

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.

Módos O, Reis H, Niedworok C, Rübben H, Szendröi A, Szász MA, Tímár J, Baghy K, Kovalszky I, Golabek T, Chlosta P, Okon K, Peyronnet B, Mathieu R, Shariat SF, Hollósi P, Nyirády P, Szarvas T.

Oncotarget. 2016 Jun 28;7(26):39293-39301. doi: 10.18632/oncotarget.9828.

25.

Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer.

Grolmusz VK, Karászi K, Micsik T, Tóth EA, Mészáros K, Karvaly G, Barna G, Szabó PM, Baghy K, Matkó J, Kovalszky I, Tóth M, Rácz K, Igaz P, Patócs A.

Am J Cancer Res. 2016 Sep 1;6(9):2041-2053. eCollection 2016.

26.

Response of Hepatic Stellate Cells to TGFB1 Differs from the Response of Myofibroblasts. Decorin Protects against the Action of Growth Factor.

Fullár A, Firneisz G, Regős E, Dudás J, Szarvas T, Baghy K, Ramadori G, Kovalszky I.

Pathol Oncol Res. 2017 Apr;23(2):287-294. doi: 10.1007/s12253-016-0095-0. Epub 2016 Aug 5.

PMID:
27495255
27.

Fluorescence activated cell sorting followed by small RNA sequencing reveals stable microRNA expression during cell cycle progression.

Grolmusz VK, Tóth EA, Baghy K, Likó I, Darvasi O, Kovalszky I, Matkó J, Rácz K, Patócs A.

BMC Genomics. 2016 May 27;17:412. doi: 10.1186/s12864-016-2747-6.

28.

Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.

Szarvas T, Reis H, Vom Dorp F, Tschirdewahn S, Niedworok C, Nyirady P, Schmid KW, Rübben H, Kovalszky I.

Prostate. 2016 Aug;76(11):977-85. doi: 10.1002/pros.23186. Epub 2016 Apr 7.

PMID:
27062540
29.

Evaluation of 9-cis retinoic acid and mitotane as antitumoral agents in an adrenocortical xenograft model.

Nagy Z, Baghy K, Hunyadi-Gulyás É, Micsik T, Nyírő G, Rácz G, Butz H, Perge P, Kovalszky I, Medzihradszky KF, Rácz K, Patócs A, Igaz P.

Am J Cancer Res. 2015 Nov 15;5(12):3645-58. eCollection 2015.

30.

Characterisation of bioenergetic pathways and related regulators by multiple assays in human tumour cells.

Jeney A, Hujber Z, Szoboszlai N, Fullár A, Oláh J, Pap É, Márk Á, Kriston C, Kralovánszky J, Kovalszky I, Vékey K, Sebestyén A.

Cancer Cell Int. 2016 Feb 11;16:4. doi: 10.1186/s12935-016-0281-x. eCollection 2016.

31.

Proteoglycans in liver cancer.

Baghy K, Tátrai P, Regős E, Kovalszky I.

World J Gastroenterol. 2016 Jan 7;22(1):379-93. doi: 10.3748/wjg.v22.i1.379. Review.

32.

BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.

Madaras L, Balint N, Gyorffy B, Tokes AM, Barshack I, Yosepovich A, Friedman E, Paluch-Shimon S, Zippel D, Baghy K, Timar J, Kovalszky I, Kulka J, Szasz AM.

Pathobiology. 2016;83(1):1-12. doi: 10.1159/000439135. Epub 2015 Nov 14.

33.

DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer.

Kalmár A, Péterfia B, Hollósi P, Galamb O, Spisák S, Wichmann B, Bodor A, Tóth K, Patai ÁV, Valcz G, Nagy ZB, Kubák V, Tulassay Z, Kovalszky I, Molnár B.

BMC Cancer. 2015 Oct 19;15:736. doi: 10.1186/s12885-015-1687-x.

34.

Polyvinyl alcohol nanofiber formulation of the designer antimicrobial peptide APO sterilizes Acinetobacter baumannii-infected skin wounds in mice.

Sebe I, Ostorhazi E, Fekete A, Kovacs KN, Zelko R, Kovalszky I, Li W, Wade JD, Szabo D, Otvos L Jr.

Amino Acids. 2016 Jan;48(1):203-11. doi: 10.1007/s00726-015-2080-4. Epub 2015 Aug 29.

PMID:
26319645
35.

Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas.

Patai ÁV, Valcz G, Hollósi P, Kalmár A, Péterfia B, Patai Á, Wichmann B, Spisák S, Barták BK, Leiszter K, Tóth K, Sipos F, Kovalszky I, Péter Z, Miheller P, Tulassay Z, Molnár B.

PLoS One. 2015 Aug 20;10(8):e0133836. doi: 10.1371/journal.pone.0133836. eCollection 2015.

36.

Chronic hyperglycemia induces trans-differentiation of human pancreatic stellate cells and enhances the malignant molecular communication with human pancreatic cancer cells.

Kiss K, Baghy K, Spisák S, Szanyi S, Tulassay Z, Zalatnai A, Löhr JM, Jesenofsky R, Kovalszky I, Firneisz G.

PLoS One. 2015 May 26;10(5):e0128059. doi: 10.1371/journal.pone.0128059. eCollection 2015.

37.

Remodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression.

Fullár A, Dudás J, Oláh L, Hollósi P, Papp Z, Sobel G, Karászi K, Paku S, Baghy K, Kovalszky I.

BMC Cancer. 2015 Apr 11;15:256. doi: 10.1186/s12885-015-1272-3.

38.

Ultrastructure and composition of thrombi in coronary and peripheral artery disease: correlations with clinical and laboratory findings.

Kovács A, Sótonyi P, Nagy AI, Tenekedjiev K, Wohner N, Komorowicz E, Kovács E, Nikolova N, Szabó L, Kovalszky I, Machovich R, Szelid Z, Becker D, Merkely B, Kolev K.

Thromb Res. 2015 Apr;135(4):760-6. doi: 10.1016/j.thromres.2015.02.004. Epub 2015 Feb 9.

PMID:
25686880
39.

Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling.

Otvos L Jr, Kovalszky I, Olah J, Coroniti R, Knappe D, Nollmann FI, Hoffmann R, Wade JD, Lovas S, Surmacz E.

Biopolymers. 2015 May;104(3):156-66. doi: 10.1002/bip.22627.

PMID:
25683126
40.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma.

Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T, Timar J, Kovalszky I, Cserepes M, Rozsas A, Laszlo V, Grusch M, Berger W, Klepetko W, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2015 May;10(5):738-46. doi: 10.1097/JTO.0000000000000492.

41.

Proteoglycans/glycosaminoglycans: from basic research to clinical practice.

Tzanakakis G, Kovalszky I, Heldin P, Nikitovic D.

Biomed Res Int. 2014;2014:295254. doi: 10.1155/2014/295254. Epub 2014 Dec 21. No abstract available.

42.

Activation of villous trophoblastic p38 and ERK1/2 signaling pathways in preterm preeclampsia and HELLP syndrome.

Szabo S, Mody M, Romero R, Xu Y, Karaszi K, Mihalik N, Xu Z, Bhatti G, Fule T, Hupuczi P, Krenacs T, Rigo J Jr, Tarca AL, Hassan SS, Chaiworapongsa T, Kovalszky I, Papp Z, Than NG.

Pathol Oncol Res. 2015 Jul;21(3):659-68. doi: 10.1007/s12253-014-9872-9. Epub 2015 Jan 13.

43.

Endogenous enzyme-hydrolyzed fruit of Cirsium brachycephalum: optimal source of the antiproliferative lignan trachelogenin regulating the Wnt/β-catenin signaling pathway in the SW480 colon adenocarcinoma cell line.

Mervai Z, Sólyomváry A, Tóth G, Noszál B, Molnár-Perl I, Baghy K, Kovalszky I, Boldizsár I.

Fitoterapia. 2015 Jan;100:19-26. doi: 10.1016/j.fitote.2014.10.017. Epub 2014 Nov 11.

PMID:
25447161
44.

Increased placental expression of cannabinoid receptor 1 in preeclampsia: an observational study.

Fügedi G, Molnár M, Rigó J Jr, Schönléber J, Kovalszky I, Molvarec A.

BMC Pregnancy Childbirth. 2014 Dec 2;14:395. doi: 10.1186/s12884-014-0395-x.

45.

Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies.

Lendvai G, Jármay K, Karácsony G, Halász T, Kovalszky I, Baghy K, Wittmann T, Schaff Z, Kiss A.

World J Gastroenterol. 2014 Nov 7;20(41):15343-50. doi: 10.3748/wjg.v20.i41.15343.

46.

Development of second generation peptides modulating cellular adiponectin receptor responses.

Otvos L Jr, Knappe D, Hoffmann R, Kovalszky I, Olah J, Hewitson TD, Stawikowska R, Stawikowski M, Cudic P, Lin F, Wade JD, Surmacz E, Lovas S.

Front Chem. 2014 Oct 17;2:93. doi: 10.3389/fchem.2014.00093. eCollection 2014.

47.

Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action.

Dudás J, Bocsi J, Fullár A, Baghy K, Füle T, Kudaibergenova S, Kovalszky I.

Biomed Res Int. 2014;2014:765794. doi: 10.1155/2014/765794. Epub 2014 Sep 7.

48.

Placental Protein 13 (PP13) - A Placental Immunoregulatory Galectin Protecting Pregnancy.

Than NG, Balogh A, Romero R, Kárpáti E, Erez O, Szilágyi A, Kovalszky I, Sammar M, Gizurarson S, Matkó J, Závodszky P, Papp Z, Meiri H.

Front Immunol. 2014 Aug 20;5:348. doi: 10.3389/fimmu.2014.00348. eCollection 2014. Review.

49.

[Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission].

Moldvay J, Pápay J, Kovalszky I, Balázs G, Puskás R, Losonczy G.

Magy Onkol. 2014 Jun;58(2):133-7. Epub 2014 Mar 5. Hungarian.

50.

[András Jeney -- 80 years].

Kovalszky I.

Magy Onkol. 2014 Mar;58(1):3. Hungarian. No abstract available.

PMID:
24864372

Supplemental Content

Loading ...
Support Center